Categories
  • Events
  • Press Release
  • Artios Pharma wins Life Science Young Company of the Year and UK Private Finance Raise at the Biotech and Money Annual Awards 2017

    Cambridge, UK, 15 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, is pleased to announce that it has won the “Life Science Young Company of the Year” and “UK Private Finance Raise of the Year” awards at last night’s Biotech and Money Awards 2017.

    15 September 2017
    Read more
    Artios Pharma appoints Dr Graeme Smith as Chief Scientific Officer

    Cambridge, UK, 4 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces the appointment of Dr Graeme Smith as its Chief Scientific Officer (CSO). 

    4 September 2017
    Read more
    Artios signs research collaboration with Masaryk University to develop novel cancer treatments targeting DNA nucleases in the DDR

    Cambridge, UK, 12 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces it has signed a research collaboration and option agreement with Masaryk University (“MU”) in the Czech Republic for the development of novel cancer treatments targeting DNA nucleases involved in the DDR.

    12 June 2017
    Read more
    Artios announces formation of world-leading Scientific Advisory Board

    Cambridge, UK, 8 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company focussed on developing innovative new treatments for cancer, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts from across Europe and the United States, in the fields of DDR, DNA genetics and drug discovery. Dr […]

    8 June 2017
    Read more
    Artios Strengthens Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy

    Artios Pharma Ltd (“Artios” or “the Company”) Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy  Cambridge, UK, 2 November 2016. Artios Pharma Ltd., a newly launched private company focussed on developing novel cancer treatments targeting the DNA Damage Response (DDR), today announces it has strengthened its management team […]

    2 November 2016
    Read more
    Artios attending the AACR conference “DNA Repair: Tumor Development and Therapeutic Response” in Montreal, Canada on Nov 2-5

    Niall Martin, CEO and Nick Staples, CBO from Artios will be attending the AACR conference “DNA Repair: Tumor Development and Therapeutic Response” in Montreal, Canada on Nov 2-5, 2016.  Artios is actively looking to expand its development pipeline with novel DDR programmes and collaborations. Please contact us at  info@artiospharma.com or call on +44 (0)1223 804180 if you would like to meet […]

    31 October 2016
    Read more
    Artios Pharma Company Launch and Fundraising of $33.2 Million to Focus on Novel DNA Damage Response (DDR) Cancer Therapies

    Artios Pharma Ltd (“Artios” or “the Company”) $33.2 Million Series A Financing from SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures to fund development of a DDR focussed pipeline Cambridge, UK, 21 September 2016. Artios Pharma Ltd., a new private company focussed […]

    21 September 2016
    Read more